madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Company profile
Ticker
MDGL
Exchange
Website
CEO
Rebecca Taub
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SYNTA PHARMACEUTICALS CORP
SEC CIK
Corporate docs
Subsidiaries
Madrigal Pharmaceuticals EU Limited, an Ireland company • Synta Limited Incorporated • Canticle Pharmaceuticals, Inc. ...
MDGL stock data
Latest filings (excl ownership)
8-K
Other Events
2 Apr 24
8-K
Entry into a Material Definitive Agreement
20 Mar 24
424B5
Prospectus supplement for primary offering
20 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
Regulation FD Disclosure
14 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
UPLOAD
Letter from SEC
25 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
Transcripts
Latest ownership filings
4
Rebecca Taub
10 Apr 24
4
PAUL A FRIEDMAN
10 Apr 24
4
Rebecca Taub
5 Apr 24
4
PAUL A FRIEDMAN
5 Apr 24
4
Richard S Levy
3 Apr 24
4
KENNETH BATE
3 Apr 24
4
James M Daly
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 62.06 mm | 62.06 mm | 62.06 mm | 62.06 mm | 62.06 mm | 62.06 mm |
Cash burn (monthly) | 5.05 mm | (no burn) | 32.84 mm | 29.05 mm | 28.31 mm | 25.23 mm |
Cash used (since last report) | 34.87 mm | n/a | 226.91 mm | 200.70 mm | 195.56 mm | 174.33 mm |
Cash remaining | 27.19 mm | n/a | -164.85 mm | -138.65 mm | -133.50 mm | -112.28 mm |
Runway (months of cash) | 5.4 | n/a | -5.0 | -4.8 | -4.7 | -4.4 |
Institutional ownership, Q3 2023
92.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 206 |
Opened positions | 34 |
Closed positions | 42 |
Increased positions | 87 |
Reduced positions | 54 |
13F shares | Current |
---|---|
Total value | 2.46 tn |
Total shares | 18.47 mm |
Total puts | 323.80 k |
Total calls | 862.70 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
JHG Janus Henderson | 3.04 mm | $444.33 bn |
Vanguard | 1.57 mm | $229.77 bn |
Avoro Capital Advisors | 1.56 mm | $227.09 bn |
Baker Bros. Advisors | 1.55 mm | $225.65 bn |
Bay City Capital | 1.51 mm | $117.96 mm |
BLK Blackrock | 1.03 mm | $150.82 bn |
STT State Street | 642.27 k | $93.80 bn |
Paulson & Co. | 500.00 k | $73.02 bn |
FMR | 440.38 k | $64.31 bn |
Marshall Wace | 395.40 k | $57.74 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 248.5907 | 4,866 | 1.21 mm | 185,735 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 247.7601 | 3,464 | 858.24 k | 190,601 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 246.959 | 5,028 | 1.24 mm | 194,065 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 245.7126 | 2,078 | 510.59 k | 199,093 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 244.8607 | 5,663 | 1.39 mm | 201,171 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 244.1197 | 3,730 | 910.57 k | 206,834 |
8 Apr 24 | Friedman Paul A | Common Stock | Sell | Dispose S | No | Yes | 242.9523 | 1,441 | 350.09 k | 210,564 |
8 Apr 24 | Friedman Paul A | Common Stock | Option exercise | Acquire M | No | No | 9.45 | 26,270 | 248.25 k | 212,005 |
8 Apr 24 | Friedman Paul A | Stock Option Common Stock | Option exercise | Dispose M | No | No | 9.45 | 26,270 | 248.25 k | 206,256 |
8 Apr 24 | Taub Rebecca | Common Stock | Sell | Dispose S | No | Yes | 248.58 | 200 | 49.72 k | 458,999 |
News
Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $405
20 Mar 24
Madrigal Pharmaceuticals Prices Upsized $600M Public Offering Of 750,000 Shares At $260/share
19 Mar 24
10 Health Care Stocks Whale Activity In Today's Session
18 Mar 24
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
15 Mar 24
UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $410
15 Mar 24
Press releases
Madrigal Statement on the Passing of Dr. Stephen Harrison
24 Apr 24
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 Apr 24
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3 Apr 24
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
18 Mar 24
Madrigal Pharmaceuticals Announces Proposed Public Offering
18 Mar 24